InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline

By Marketwired .

Article Rating:

June 3, 2015 06:00 AM EDT



VANCOUVER, BRITISH COLUMBIA — (Marketwired) — 06/03/15 — InMed Pharmaceuticals Inc. (“InMed”) (CSE:IN)(OTCQB:IMLFF), a clinical ~-wagon biopharmaceutical company that specializes in developing safer, besides effective cannabis-based therapies, announced it has initiated a program to identify and evaluate cannabinoid compounds for the management of chronic obstructive pulmonary disease (COPD). Initial remedy discovery and preclinical development is currently underway in collaboration with members of the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia.

Craig Schneider, President & Chief Executive Officer, detailed, “We’re excited to explore avenues to more remote expand InMed’s pipeline with the adding of new program targeting COPD, the third part leading cause of death in the United States. Similar to our ongoing program in orofacial incommode, we are leveraging our proprietary keen-sighted drug design platform technology to sameness promising therapeutic candidates. In addition to advancing our current fruits candidates, expansion into respiratory disease marks our fourth greater disease focus, highlighting our commitment to fabric a leading pipeline of cannabinoid-based therapies.”

Dr. Sazzad Hossain, Chief Scientific Officer, regular, “Current treatments for COPD are compounded and ineffective and there is generally no cure available. It is well known that cannabinoids disclose bronchodilatory, immunosuppressive, and anti-inflammatory properties and to this degree cannabinoid-based therapy may offer safer and besides effective treatment options for COPD.”

InMed researcher, Dr. Dmitri Pechkovsky, inclination conduct the initial discovery work in the laboratory of Dr. Pascal Bernatchez at the University of British Columbia. Dr. Pechkovsky has large research experience in pulmonary disorders, specifically, COPD, idiopathic pulmonic fibrosis, and asthma. He earned his Ph.D. in Immunology and Allergy from Minsk State Medical Institute in Belarus and conducted station-doctoral training at the Research Center Borstel-Leibniz Center against Medicine and Biosciences (FZB), Luebeck University, and University of Freiburg in Germany.

About COPD

Chronic obstructive pulmonary disease (COPD) is a chronic ail of the lower respiratory tract in the lungs that makes it progressively additional difficult to breathe. Currently, over 50 the great body of the people people globally have been diagnosed with COPD. However, studies estimate the very prevalence of COPD is twice that result. According to the Centers for Disease Control and Prevention (CDC), COPD is the third part leading cause of death in the United States.

The illness typically develops as a result of inhalation of air pollutants including cigarette exhale, air pollution, chemical fumes, and dust. Those who bear from COPD show symptoms including terseness of breath, increased production of mucus, coughing, and chest tightness, caused by the restricted airflow through airways in the lungs. Currently, in that place is no definitive cure for COPD, unless a variety of treatments do exist.

About Cannabinoid-based Therapy for COPD

Recent studies hold indicated that cannabinoid-based therapy may have ~ing effective in ameliorating major symptoms of COPD. THC, the major active ingredient in cannabis, has been shown to present to view bronchodilation for up to two hours afterward administration. To counteract the heightened COPD-induced immune rejoinder in the lungs, THC mobilizes myeloid-derived suppressor cells (MDSCs), a form into ~s of white blood cells, which bar T-cell proliferation and activation. Cannabinoids too exhibit anti-inflammatory effects through the inhibition of cyclooxygenases COX-1 and COX-2, enzymes that extend inflammatory compounds.

About InMed

InMed Pharmaceuticals is a publicly-traded clinical-field biopharmaceutical company specializing in developing therapies end research and development into the extensive pharmacology of cannabinoids coupled with innovative medicine delivery systems. InMed’s development pipeline includes effect candidates for glaucoma, arthritis, and epidermoylsis bullosa (EBS), as well as active discovery programs in orofacial discomfort, ocular allergies, and chronic obstructive pulmonic disease (COPD). InMed’s proprietary Intelligent Cannabinoid Drug Design Platform (IDP), therapeutic product pipeline, and accelerated development pathway are the fundamental value drivers of the Company.


InMed Pharmaceuticals Inc.

Craig Schneider, President and Chief Executive Officer

Forward Looking Statements

This news release may contain forward-looking statements and advice based on current expectations. These statements should not be read as guarantees of future completion or results. Such statements involve known and unexplored risks, uncertainties and other factors that may case actual results, performance or achievements to subsist materially different from those implied ~ dint of. such statements. Although such statements are based up~ management’s reasonable assumptions, there be possible to be no assurance that such assumptions power of determination prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, exhibition or achievements to be materially separate from any future results, performance or achievements expressed or implied ~ means of the forward-looking information contained in this respect.

All forward-looking information herein is competent in its entirety by this cautionary recital, and InMed Pharmaceuticals disclaims any covenant to revise or update any so forward-looking information or to publicly give notice of the result of any revisions to at all of the forward-looking information contained in this to reflect future results, events or developments, exclude as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or fix earlier clinical trial results, risks associated through obtaining funding from third parties, risks kindred to the timing and costs of clinical trials and the quittance of regulatory approvals


Copyright © 2009 Marketwired. All rights demure. All the news releases provided ~ means of Marketwired are copyrighted. Any forms of copying other than one individual user’s personal reference lacking express written permission is prohibited. Further partition of these materials is strictly forbidden, including however not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer netting or in a printed form.

Latest Stories

By Elizabeth White

SYS-CON Events announced today order exhibit at SYS-CON’s DevOps Summit 2015 New York, what one. will take place June 9-11, 2015, at the Javits Center in New York City, NY. Launched in 2014, has with haste established itself as an indispensable resort for DevOps education and community edifice. make it their business to cover all aspects of DevOps – philosophy, tools, business impact, best practices and further.

Jun. 3, 2015 02:45 PM EDT  Reads: 693

By Liz McMillan

Explosive advance in connected devices. Enormous amounts of facts for collection and analysis. Critical exercise of data for split-second conclusion making and actionable information. All three are factors in composition the Internet of Things a actuality. Yet, any one factor would own an IT organization pondering its infrastructure strategy. How should your organization enhance its IT frame to enable an Internet of Things implementation? In this session, James Kirkland, Red Hat’s Chief Architect as being the …

Jun. 3, 2015 02:30 PM EDT  Reads: 1,244

By Pat Romanski

ProfitBricks has an early preview of its new Docker hosting platform. The ProfitBricks Docker platform enables its customers to model fully-portable applications within the ProfitBricks vapor. Unlike other Docker platforms, ProfitBricks’ Docker provides developers and plan administrators with a platform with dedicated available means that autoscales the Docker hosts. Early entranceway customers will be able to turn to account up to 2,500 CPU essence hours as part of ProfitBricks’ in season access Docker preview.

Jun. 3, 2015 02:30 PM EDT  Reads: 522

By Pat Romanski

“DevOps is positively about the business. The business is in a less degree than pressure today, competitively in the marketplace to respond to the expectations of the buyer. The business is driving IT and the enigma is that IT isn’t responding fortified enough,” explained Mark Levy, Senior Product Marketing Manager at Serena Software, in this conference at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.

Jun. 3, 2015 02:15 PM EDT  Reads: 4,244

By Elizabeth White

Aria Systems, that helps enterprises grow recurring revenue, today announced that its co-originator and inventor of cloud billing Brendan O’Brien, exercise volition be a featured speaker at the Cloud Expo, June 9-11 at The Javits Center in New York. Aria furthermore will be demonstrating its Active Monetization platform in Booth #424 up~ the Expo Floor. O’Brien elect lead the following sessions: June 9 – 11:00 am – 11:35 am, Room 1A16 by participants from Constant Contact, MGI Research and ATG Enabling Complex …

Jun. 3, 2015 02:15 PM EDT  Reads: 438

By Liz McMillan

IBM has acquired Blue Box Group, Inc., a managed special cloud provider built on OpenStack. Customers favor from the ability to more easily expand workloads across hybrid cloud environments. Financial minor circumstances were not disclosed. Enterprises are seeking ways to comprise all types of cloud to art a wide range of workloads. Today’s manifesto reinforces IBM’s commitment to make over flexible cloud computing models that go it easier for customers to stir to data and applications across host…

Jun. 3, 2015 02:15 PM EDT  Reads: 577

By Elizabeth White

Growth hacking is frequent for startups to make unheard-of progress in pile their business. Career Hacks can assist Geek Girls and those who assistance them (yes, that’s you in addition, Dad!) to excel in this typically male-dominated world. Get ready to learn the facts: Is in that place a bias against women in the tech / developer communities? Why are women 50% of the workforce, goal hold only 24% of the STEM or IT positions? Some beginnings of that which to do about it!

Jun. 3, 2015 02:00 PM EDT  Reads: 1,180

By Roger Strukhoff

Andi Mann has been serving being of the kind which Conference Chair of the DevOps Summit inasmuch as its inception. He is one of the universe‘s recognized leaders in DevOps, and continues to exist one of its most articulate advocates. Here are some recent thoughts of his in ~y interview we conducted in the go-up to the DevOps Summit to subsist held June 9-11 at the Javits Center in New York City. When did you before anything else start thinking about DevOps and its in posse impact on enterprise IT? Andi: I earliest started thinking about DevOps b…

Jun. 3, 2015 02:00 PM EDT  Reads: 1,188

By Elizabeth White

“ElasticBox is ~y enterprise company that makes it real easy for developers and IT ops to collaborate to unfold, build and deploy applications on some cloud – private, public or hybrid,” fixed Monish Sharma, VP of Customer Success at ElasticBox, in this conference at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.

Jun. 3, 2015 02:00 PM EDT  Reads: 4,733

By Elizabeth White

The WebRTC Meetup, where WebRTC enthusiasts exchange ideas, is existence held on Wednesday, June 10, from 7 pm – 9 pm at the 4th WebRTC Summit, June 9-11, 2015, at the Javits Center in New York City, NY. The WebRTC Meetup is subsistence hosted by the New York WebRTC Developer Group. WebRTC is the future of browser-to-browser communications, and continues to tend inroads into the traditional, difficult, plug-in web communications world. The 4th WebRTC Summit continues our delivery of delivering the late…

Jun. 3, 2015 02:00 PM EDT  Reads: 461

By Elizabeth White

The willingness to make ventures market will drive IoT device affiliation over the next five years. In his session at @ThingsExpo, John Greenough, an analyst at BI Intelligence, division of Business Insider, command analyze how companies will adopt IoT products and the associated cost of adopting those products. John Greenough is the contribute analyst covering the Internet of Things ~ the sake of BI Intelligence- Business Insider’s paid study service. Numerous IoT companies have cited his resolution of the IoT. Prior to joining B…

Jun. 3, 2015 01:45 PM EDT  Reads: 1,052

By Pat Romanski

SYS-CON Events announced today that O’Reilly Media has been named “Media Sponsor” of SYS-CON’s 16th International Cloud Expo®, what one. will take place on June 9–11, 2015, at the Javits Center in New York City, NY. O’Reilly Media spreads the discernment of innovators through its books, online services, magazines, and conferences. Since 1978, O’Reilly Media has been a chronicler and catalyst of cutting-edge disentanglement, homing in on the technology trends that absolutely matter and spurring their adoption…

Jun. 3, 2015 01:30 PM EDT  Reads: 1,270

By Pat Romanski

The basic integration science, as defined by ESBs, hasn’t changed with regard to more than a decade. Most collection of vapor integration providers still rely on ~y ESB architecture and their proprietary connectors. As a terminate, enterprise integration projects suffer from constraints of availability and reliability of these connectors that are not re-usable thwart other integration vendors. However, the quick adoption of APIs and almost ubiquitary availability of APIs amongst most SaaS and Cloud applications are ra…

Jun. 3, 2015 01:30 PM EDT  Reads: 865

By Liz McMillan

SYS-CON Events announced today that SUSE, a pioneer in commence source software, will exhibit at SYS-CON’s DevOps Summit 2015 New York, that will take place June 9-11, 2015, at the Javits Center in New York City, NY. SUSE provides reliable, interoperable Linux, cloud infrastructure and storage solutions that accord. enterprises greater control and flexibility. More than 20 years of engineering transcendence, exceptional service and an unrivaled sharer ecosystem power the products and bread that help …

Jun. 3, 2015 01:15 PM EDT  Reads: 1,295

By AppDynamics Blog

It’s in ~ degree news that microservices are one of the upper end trends, if not the top ~ing, in application architectures today. Take wide monolithic applications which are brittle and hard to be understood to change and break them into smaller tamable pieces to provide flexibility in deployment models, facilitating alert release and development to meet today’s swiftly shifting digital businesses. Unfortunately, with this modify, application and infrastructure management is to a greater degree complex due to size and technology c…

Jun. 3, 2015 01:15 PM EDT  Reads: 309


Oxycodone often proves to be mistakenly known for example oxycotton.

Recent Comments